[go: up one dir, main page]

WO2005047536A3 - Detection d'amplification et de deletion genomiques dans le cancer - Google Patents

Detection d'amplification et de deletion genomiques dans le cancer Download PDF

Info

Publication number
WO2005047536A3
WO2005047536A3 PCT/EP2004/012876 EP2004012876W WO2005047536A3 WO 2005047536 A3 WO2005047536 A3 WO 2005047536A3 EP 2004012876 W EP2004012876 W EP 2004012876W WO 2005047536 A3 WO2005047536 A3 WO 2005047536A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
deletion
detection
genomic amplification
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2004/012876
Other languages
English (en)
Other versions
WO2005047536A2 (fr
Inventor
Marlene Michelle Dressman
Rachel Helene Malinowski
Mihael Hristos Polymeropoulos
Alex Baras
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Pharma GmbH Austria
Novartis AG
Original Assignee
Novartis Pharma GmbH Austria
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma GmbH Austria, Novartis AG filed Critical Novartis Pharma GmbH Austria
Publication of WO2005047536A2 publication Critical patent/WO2005047536A2/fr
Publication of WO2005047536A3 publication Critical patent/WO2005047536A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une amplification et/ou une délétion génomiques dans des tissus cancéreux et des procédés et compositions de diagnostic et de traitement du cancer. Le procédé selon l'invention consiste à mettre en oeuvre la combinaison de profilage d'expression génique et la cartographie génétique et l'identification de gènes spécifiques s'avérant être co-amplifiés avec le gène c-erb B2 dans le cancer du sein.
PCT/EP2004/012876 2003-11-13 2004-11-12 Detection d'amplification et de deletion genomiques dans le cancer Ceased WO2005047536A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51984503P 2003-11-13 2003-11-13
US60/519,845 2003-11-13

Publications (2)

Publication Number Publication Date
WO2005047536A2 WO2005047536A2 (fr) 2005-05-26
WO2005047536A3 true WO2005047536A3 (fr) 2005-08-11

Family

ID=34590454

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/012876 Ceased WO2005047536A2 (fr) 2003-11-13 2004-11-12 Detection d'amplification et de deletion genomiques dans le cancer

Country Status (1)

Country Link
WO (1) WO2005047536A2 (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8664194B2 (en) 2011-12-16 2014-03-04 Moderna Therapeutics, Inc. Method for producing a protein of interest in a primate
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US8999380B2 (en) 2012-04-02 2015-04-07 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
US9107886B2 (en) 2012-04-02 2015-08-18 Moderna Therapeutics, Inc. Modified polynucleotides encoding basic helix-loop-helix family member E41
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9334328B2 (en) 2010-10-01 2016-05-10 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US9428535B2 (en) 2011-10-03 2016-08-30 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP3052106A4 (fr) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucléotides codant des polypeptides de modulation immunitaire
EA201690675A1 (ru) 2013-10-03 2016-08-31 Модерна Терапьютикс, Инк. Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности
CN109022366A (zh) * 2018-08-16 2018-12-18 江南大学 一株分泌抗左旋咪唑单克隆抗体的杂交瘤细胞株及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001015730A1 (fr) * 1999-08-27 2001-03-08 Genentech, Inc. DOSAGES POUR TRAITEMENT AVEC DES ANTICORPS ANTI-ErbB2
US20020187474A1 (en) * 2000-05-02 2002-12-12 City Of Hope Polymorphisms in the PNMT gene
US20030157523A1 (en) * 2001-11-20 2003-08-21 Genentech, Inc. Cell and tissue arrays and microarrays and methods of use
US20040018525A1 (en) * 2002-05-21 2004-01-29 Bayer Aktiengesellschaft Methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasma

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001015730A1 (fr) * 1999-08-27 2001-03-08 Genentech, Inc. DOSAGES POUR TRAITEMENT AVEC DES ANTICORPS ANTI-ErbB2
US20020187474A1 (en) * 2000-05-02 2002-12-12 City Of Hope Polymorphisms in the PNMT gene
US20030157523A1 (en) * 2001-11-20 2003-08-21 Genentech, Inc. Cell and tissue arrays and microarrays and methods of use
US20040018525A1 (en) * 2002-05-21 2004-01-29 Bayer Aktiengesellschaft Methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasma

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DRESSMAN MARLENE A ET AL: "Gene expression profiling detects gene amplification and differentiates tumor types in breast cancer.", CANCER RESEARCH, vol. 63, no. 9, 1 May 2003 (2003-05-01), pages 2194 - 2199, XP002319459, ISSN: 0008-5472 *
KAURANIEMI P ET AL: "New amplified and highly expressed genes discovered in the ERBB2 amplicon in breast cancer by cDNA microarrays", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 61, no. 22, 15 November 2001 (2001-11-15), pages 8235 - 8240, XP002264781, ISSN: 0008-5472 *
KAURANIEMI PAIVIKKI ET AL: "Amplification of a 0.2 Mb core region at the ERBB2 locus leads to activation of a small set of genes in breast cancer.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 44, July 2003 (2003-07-01), & 94TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH; WASHINGTON, DC, USA; JULY 11-14, 2003, pages 242, XP001205287, ISSN: 0197-016X *
MOOG-LUTZ C ET AL: "MLN64 EXHIBITS HOMOLOGY WITH THE STEROIDOGENIC ACUTE REGULATORY PROTEIN (STAR) AND IS OVER-EXPRESSED IN HUMAN BREAST CARCINOMAS", INTERNATIONAL JOURNAL OF CANCER, NEW YORK, NY, US, vol. 71, no. 2, 10 April 1997 (1997-04-10), pages 183 - 191, XP001004431, ISSN: 0020-7136 *
POLYMEROPOULOS M H ET AL: "Detecting gene amplification in breast cancer by combining Gene expression profiling and Gene mapping", AMERICAN JOURNAL OF HUMAN GENETICS, vol. 69, no. 4 Supplement, October 2001 (2001-10-01), & 51ST ANNUAL MEETING OF THE AMERICAN SOCIETY OF HUMAN GENETICS; SAN DIEGO, CALIFORNIA, USA; OCTOBER 12-16, 2001, pages 259, XP009044500, ISSN: 0002-9297 *

Cited By (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9447164B2 (en) 2010-08-06 2016-09-20 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9334328B2 (en) 2010-10-01 2016-05-10 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US9533047B2 (en) 2011-03-31 2017-01-03 Modernatx, Inc. Delivery and formulation of engineered nucleic acids
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9428535B2 (en) 2011-10-03 2016-08-30 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US9186372B2 (en) 2011-12-16 2015-11-17 Moderna Therapeutics, Inc. Split dose administration
US8754062B2 (en) 2011-12-16 2014-06-17 Moderna Therapeutics, Inc. DLIN-KC2-DMA lipid nanoparticle delivery of modified polynucleotides
US8680069B2 (en) 2011-12-16 2014-03-25 Moderna Therapeutics, Inc. Modified polynucleotides for the production of G-CSF
US9295689B2 (en) 2011-12-16 2016-03-29 Moderna Therapeutics, Inc. Formulation and delivery of PLGA microspheres
US9271996B2 (en) 2011-12-16 2016-03-01 Moderna Therapeutics, Inc. Formulation and delivery of PLGA microspheres
US8664194B2 (en) 2011-12-16 2014-03-04 Moderna Therapeutics, Inc. Method for producing a protein of interest in a primate
US9220792B2 (en) 2012-04-02 2015-12-29 Moderna Therapeutics, Inc. Modified polynucleotides encoding aquaporin-5
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9216205B2 (en) 2012-04-02 2015-12-22 Moderna Therapeutics, Inc. Modified polynucleotides encoding granulysin
US9149506B2 (en) 2012-04-02 2015-10-06 Moderna Therapeutics, Inc. Modified polynucleotides encoding septin-4
US9221891B2 (en) 2012-04-02 2015-12-29 Moderna Therapeutics, Inc. In vivo production of proteins
US9220755B2 (en) 2012-04-02 2015-12-29 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with blood and lymphatic disorders
US9233141B2 (en) 2012-04-02 2016-01-12 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with blood and lymphatic disorders
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9114113B2 (en) 2012-04-02 2015-08-25 Moderna Therapeutics, Inc. Modified polynucleotides encoding citeD4
US9192651B2 (en) 2012-04-02 2015-11-24 Moderna Therapeutics, Inc. Modified polynucleotides for the production of secreted proteins
US9107886B2 (en) 2012-04-02 2015-08-18 Moderna Therapeutics, Inc. Modified polynucleotides encoding basic helix-loop-helix family member E41
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9301993B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides encoding apoptosis inducing factor 1
US9095552B2 (en) 2012-04-02 2015-08-04 Moderna Therapeutics, Inc. Modified polynucleotides encoding copper metabolism (MURR1) domain containing 1
US9089604B2 (en) 2012-04-02 2015-07-28 Moderna Therapeutics, Inc. Modified polynucleotides for treating galactosylceramidase protein deficiency
US9061059B2 (en) 2012-04-02 2015-06-23 Moderna Therapeutics, Inc. Modified polynucleotides for treating protein deficiency
US9050297B2 (en) 2012-04-02 2015-06-09 Moderna Therapeutics, Inc. Modified polynucleotides encoding aryl hydrocarbon receptor nuclear translocator
US8999380B2 (en) 2012-04-02 2015-04-07 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
US9675668B2 (en) 2012-04-02 2017-06-13 Moderna Therapeutics, Inc. Modified polynucleotides encoding hepatitis A virus cellular receptor 2
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA

Also Published As

Publication number Publication date
WO2005047536A2 (fr) 2005-05-26

Similar Documents

Publication Publication Date Title
WO2005047536A3 (fr) Detection d'amplification et de deletion genomiques dans le cancer
WO2007143752A3 (fr) Cibles pour le pronostic ou la thérapie dans le cancer du sein
WO2002086448A3 (fr) Detection de l'instabilite des microsatellites et son utilisation dans le diagnostic des tumeurs
EP2295604A3 (fr) Diagnostic et traitement de cancers à l'aide de microARN présent dans ou au voisinage de caractéristiques chromosomiques associées aux cancers
NZ577805A (en) Genetic markers for risk management of cardiac arrhythmia
WO2004065583A3 (fr) Marqueurs d'expression genique pour le pronostic du cancer du sein
EP2540840A3 (fr) Variants génétiques du CHR16 utilisés comme marqueurs dans l'évaluation, le diagnostic, le pronostic et le traitement d'un risque de cancer du sein
WO2008088860A3 (fr) Polymorphismes présents dans la voie de signalisation de l'egfr utilisés comme marqueurs pour le traitement du cancer
NZ593628A (en) Genetic variants useful for risk assessment of thyroid cancer using rs944289
WO2004076639A8 (fr) Compositions et methodes destinees a diagnostiquer et traiter des maladies auto-immunes
NZ600407A (en) Diagnosing cancer using genomic sequencing
WO2004111273A3 (fr) Marqueurs d'expression genique utilises en vue d'une reaction a des medicaments inhibiteurs de egfr
WO2006110855A3 (fr) Procedes de determination de variantes de sequence utilisant un sequencage des amplicons
WO2009009432A3 (fr) Fusions géniques récurrentes dans le cancer de la prostate
WO2007095316A3 (fr) Compositions et procédés pour formulations à base d'oligonucléotides
WO2005044990A3 (fr) Sequences d'acide nucleique differemment exprimees utilisees comme biomarqueurs du cancer
WO2004097052A3 (fr) Procedes de pronostic et de traitement de tumeurs solides
WO2008088861A3 (fr) Polymorphismes géniques prédictifs d'une bithérapie à base de tki
WO2009074328A3 (fr) Methodes et acides nucleiques permettant d'analyser les troubles de la proliferation cellulaire
WO2009105590A3 (fr) Identification de loci de maladie intestinale inflammatoire à début pédiatrique et ses procédés d'utilisation pour son diagnostic et son traitement
WO2008088893A3 (fr) Polymorphismes génétiques dans le vegf et le récepteur 2 du vegf en tant que marqueurs pour une thérapie contre le cancer
WO2007028161A3 (fr) Procédés et compositions permettant d’identifier des biomarqueurs utiles au diagnostic et/ou au traitement d’états biologiques
MX2010005060A (es) Identificacion y mapeo a base de microarreglos de adn de puntos de ruptura de translocacion equilibrados.
WO2008073629A3 (fr) Predicteurs bifonctionnels de sensibilite et de resistance a un traitement anti-cancereux
WO2005001138A3 (fr) Survie apres cancer du sein et recurrence de ce type de cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase